The document provides an overview of the global respiratory drug market from 2005-2014. It discusses key details like market growth in the US, therapeutic segment market shares for conditions like asthma and COPD, and the mechanisms and sales of common delivery devices like dry powder inhalers and metered dose inhalers. The document also analyzes major companies in the space like GSK, AstraZeneca, Boehringer Ingelheim, and Teva and their respiratory drug portfolios and pipelines. Devices are highlighted as a major differentiator and driver of revenue, with combination DPIs generating over $10 billion in branded sales annually.